Special Interview with Prof. Amedeo Amedei, The University of Florence
On June 19, 2026, Hepatoma Research had the pleasure of interviewing Prof. Amedeo Amedei from the University of Florence, Italy, to welcome him as a new member of the journal's Editorial Board.
Prof. Amedei is a Full Professor of Immunology whose research focuses on tumor immunology, chronic inflammation, the microbiota–immunity axis, and translational medicine. Throughout his career, he has made important contributions to understanding T-cell functional polarization, immune-mediated inflammation, and the complex interactions between the immune system, microbiota, and disease microenvironments. His work spans cancer, autoimmune diseases, chronic inflammatory disorders, and neurodegenerative diseases, with a particular emphasis on immune regulation and microbiome research.
As a newly appointed Editorial Board Member, Prof. Amedei will contribute his expertise in tumor immunology and immune microenvironment research to support the journal's continued development in liver cancer and related liver diseases.
During the interview, Prof. Amedei discussed his research on tumor immunology, chronic inflammation, and the microbiota–immunity axis, highlighting the importance of interdisciplinary approaches in advancing liver cancer research. He shared his perspectives on the role of gut microbiota in shaping liver immunity, influencing the tumor microenvironment, and affecting treatment responses. In addition, he expressed his vision for the future development of Hepatoma Research and introduced the scientific focus of the upcoming Special Issue, encouraging submissions addressing tumor immunity, immune resistance, microbiota–immune interactions, and innovative immunotherapeutic strategies in hepatocellular carcinoma.
We sincerely thank Prof. Amedei for sharing his valuable insights and perspectives. We are delighted to welcome him to the Editorial Board of Hepatoma Research and look forward to working closely with him to promote high-quality research and academic exchange in liver cancer, immunology, and translational medicine.
Interview Questions:
Q1：Congratulations on joining the Editorial Board of Hepatoma Research. Could you briefly introduce your current research interests and what motivated your long-term focus on immunology?
Q2：Recent studies suggest that immune dysregulation and microbiome alterations are common features across cancer, autoimmune disorders, and neurodegenerative diseases. How can cross-disciplinary research accelerate discoveries in liver disease and hepatocellular carcinoma?
Q3：Your research has extensively explored the microbiota–immunity axis. How do you envision the role of the gut microbiome in shaping liver immunity and influencing hepatocellular carcinoma development or treatment response?
Q4：As a newly appointed Editorial Board Member of Hepatoma Research, what suggestions do you have for the journal's future development? In addition, what contributions do you hope to make during your two-year term to help strengthen the journal's scientific impact and international visibility?
Q5：As Guest Editor of the upcoming Special Issue on Immunology, what types of studies would you particularly like to attract from the research community?
About the Interviewee:
Prof. Amedeo Amedei is Full Professor of Immunology at the University of Florence, Italy. His research interests include tumor immunology, immune-mediated inflammation, the microbiota–immunity axis, and translational medicine. He has made important contributions to the characterization of T-cell subsets and the understanding of immune dysregulation in cancer and chronic inflammatory diseases. His work has advanced knowledge of the interactions between immunity, microbiota, and the tumor microenvironment, providing important insights into immune modulation and immunotherapeutic strategies. Prof. Amedei has published more than 320 peer-reviewed articles (h-index 60; >15,000 citations) and is internationally recognized for his contributions to tumor immunology and microbiome research.
Editor: Vivienne Yan
Production Editor: Ting Xu
Respectfully Submitted by the Editorial Office of Hepatoma Research
